ChitogenX Inc. (CHNXF)
USD 0.01
(-13.38%)
USD 0.01
(-13.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -2.69 Million CAD | 43.26% |
| 2023 | -4.74 Million CAD | -40.41% |
| 2022 | -3.44 Million CAD | -15.85% |
| 2021 | -2.54 Million CAD | -31.23% |
| 2020 | -2.06 Million CAD | 8.57% |
| 2019 | -2.21 Million CAD | -23.91% |
| 2018 | -1.87 Million CAD | -8.56% |
| 2017 | -105.83 Thousand CAD | -177.92% |
| 2016 | -265.53 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -380 Thousand CAD | 37.81% |
| 2024 Q1 | -1.46 Million CAD | -23.52% |
| 2024 Q4 | -734 Thousand CAD | -93.16% |
| 2024 FY | - CAD | 42.31% |
| 2024 Q2 | -611 Thousand CAD | 58.29% |
| 2023 Q4 | -1.18 Million CAD | 1.0% |
| 2023 Q1 | -1.25 Million CAD | -37.68% |
| 2023 Q2 | -1.11 Million CAD | 11.22% |
| 2023 FY | - CAD | -40.41% |
| 2023 Q3 | -1.19 Million CAD | -7.35% |
| 2022 Q3 | -991 Thousand CAD | -73.25% |
| 2022 FY | - CAD | -15.85% |
| 2022 Q4 | -913 Thousand CAD | 7.87% |
| 2022 Q2 | -572 Thousand CAD | 37.89% |
| 2022 Q1 | -921 Thousand CAD | 3.26% |
| 2021 Q3 | -608 Thousand CAD | -48.66% |
| 2021 Q2 | -409 Thousand CAD | 52.55% |
| 2021 Q1 | -862 Thousand CAD | -218.08% |
| 2021 Q4 | -952 Thousand CAD | -56.58% |
| 2021 FY | - CAD | -31.23% |
| 2020 Q2 | -532 Thousand CAD | -2.31% |
| 2020 Q3 | -683 Thousand CAD | -28.38% |
| 2020 Q4 | -271 Thousand CAD | 60.32% |
| 2020 FY | - CAD | 8.57% |
| 2020 Q1 | -520 Thousand CAD | 21.81% |
| 2019 Q3 | -714 Thousand CAD | -63.01% |
| 2019 Q1 | -399 Thousand CAD | 29.79% |
| 2019 Q2 | -438 Thousand CAD | -9.77% |
| 2019 Q4 | -665.02 Thousand CAD | 6.86% |
| 2019 FY | - CAD | -23.91% |
| 2018 Q3 | -587.69 Thousand CAD | -73.23% |
| 2018 Q2 | -339.25 Thousand CAD | -45.71% |
| 2018 Q1 | -232.83 Thousand CAD | -43.09% |
| 2018 Q4 | -568.27 Thousand CAD | 3.3% |
| 2018 FY | - CAD | -8.56% |
| 2017 Q2 | -539.05 Thousand CAD | -99.47% |
| 2017 Q4 | -162.71 Thousand CAD | 64.84% |
| 2017 FY | - CAD | -177.92% |
| 2017 Q1 | -270.24 Thousand CAD | 59.25% |
| 2017 Q3 | -462.82 Thousand CAD | 14.14% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q1 | -36.53 Thousand CAD | 0.0% |
| 2016 Q2 | -53.58 Thousand CAD | -46.68% |
| 2016 Q3 | -166.68 Thousand CAD | -211.07% |
| 2016 Q4 | -663.12 Thousand CAD | -297.83% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | 12.047% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 24.048% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -17.926% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 84.491% |
| GB Sciences, Inc. | -1.41 Million USD | -89.734% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 811.111% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -21929.602% |
| Skye Bioscience, Inc. | -13.54 Million USD | 80.114% |
| Zenith Capital Corp. | -8.6 Million USD | 68.696% |
| Agentix Corp. | -1.37 Million USD | -96.391% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 30.644% |
| Biomind Labs Inc. | -1.03 Million USD | -160.403% |
| ContraFect Corporation | -64.99 Million USD | 95.855% |
| CSL Limited | 4.78 Billion USD | 100.056% |
| CytoDyn Inc. | -18.02 Million USD | 85.057% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 40165.437% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -325.992% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.132% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -633.618% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -75.385% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -187.529% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.865% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.8% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -81.12% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.208% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1.874% |
| Mesoblast Limited | -62.38 Million USD | 95.682% |
| Marizyme, Inc. | -34.28 Million USD | 92.142% |
| Genus plc | 73.7 Million USD | 103.655% |
| Pharming Group N.V. | 9.87 Million USD | 127.275% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 69.289% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -92.18% |
| IMV Inc. | -35.52 Million USD | 92.416% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -15.93% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -420.031% |
| ONE Bio Corp. | 13.61 Million USD | 119.79% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 94.414% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 175.42% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 6.857% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 62.381% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -10676.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 83.024% |
| Alpha Cognition Inc. | -9.7 Million USD | 72.243% |
| Enzolytics Inc. | -2.12 Million USD | -26.954% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 98.753% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 321.364% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 130.428% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.917% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 54.562% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1026.49% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -10.118% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1430.47% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -40.246% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 59.253% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 40.48% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 28.091% |
| Helix BioMedix, Inc. | -1.04 Million USD | -157.476% |
| EV Biologics, Inc. | -1.26 Million USD | -112.606% |
| Q BioMed Inc. | -617.62 Thousand USD | -336.185% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -53.943% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 93.203% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 64.335% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -7.675% |
| HST Global, Inc. | -5303.00 USD | -50701.433% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -30.967% |
| Halberd Corporation | -74.27 Thousand USD | -3526.866% |
| Resverlogix Corp. | -11.74 Million USD | 77.057% |
| Cell Source, Inc. | -4.27 Million USD | 36.946% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -79.731% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | 55.927% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -15364.095% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -160.341% |
| Kadimastem Ltd | -2.62 Million USD | -2.653% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -609.657% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1387.675% |
| LadRx Corporation | 412.28 Thousand USD | 753.435% |
| Regen BioPharma, Inc. | 1.46 Million USD | 283.771% |
| Affymax, Inc. | -14.29 Million USD | 81.154% |
| Itoco Inc. | -1.86 Million USD | -44.142% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -141.398% |
| Mobile Lads Corp. | -2.24 Million USD | -20.206% |
| International Stem Cell Corporation | 202 Thousand USD | 1433.663% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | 29.479% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3308.875% |
| Qrons Inc. | -40.08 Thousand USD | -6621.389% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -454.688% |
| SYBLEU INC | -141.57 Thousand USD | -1802.932% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 610.776% |
| Rebus Holdings, Inc. | -951 Thousand USD | -183.281% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -153.67% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5017.781% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -9.426% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 92.489% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5886.667% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 1.607% |
| Neutra Corp. | -181.24 Thousand USD | -1386.369% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 86.636% |
| PureTech Health plc | -11.62 Million USD | 76.83% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 86.635% |
| IXICO plc | -707 Thousand USD | -281.047% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 64.945% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 94.428% |
| CSL Limited | 4.73 Billion USD | 100.057% |
| Cellectis S.A. | -92.63 Million USD | 97.092% |